Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCA00186 + retifanlimab + INCB106385
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination investigational therapy composed of **INCA00186** (a CD73 inhibitor), **retifanlimab** (a programmed death-1 (PD-1) receptor blocking monoclonal antibody, also known and approved as Zynyz for some indications), and **INCB106385** (a small molecule inhibitor targeting A2A and A2B adenosine receptors); developed by Incyte. This multi-agent regimen is currently under evaluation in phase 1 clinical trials for patients with advanced solid tumors, specifically those with CD8 T-cell-positive cancers such as squamous cell carcinoma of the head and neck and selected gastrointestinal malignancies. The combination is designed to enhance antitumor immunity by simultaneously relieving adenosine-mediated immunosuppression (via CD73 and A2A/B inhibition) and restoring T cell activity through PD-1 blockade[1][3][5].
- Other names
- INCA 0186 + INCB106385 + retifanlimab
02
Targets
ADORA2A (Adenosine A₂A Receptor)PDCD1 (Programmed cell death protein 1 receptor)ADORA2B (Adenosine A2B receptor)NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on INCA00186 + retifanlimab + INCB106385.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCA00186 + retifanlimab + INCB106385.